NO303632B1 - Imidazolderivater med bifenylsulfonylurea- eller bifenylsulfonyluretan-sidekjeder samt preparat inneholdende et slikt derivat - Google Patents

Imidazolderivater med bifenylsulfonylurea- eller bifenylsulfonyluretan-sidekjeder samt preparat inneholdende et slikt derivat

Info

Publication number
NO303632B1
NO303632B1 NO930817A NO930817A NO303632B1 NO 303632 B1 NO303632 B1 NO 303632B1 NO 930817 A NO930817 A NO 930817A NO 930817 A NO930817 A NO 930817A NO 303632 B1 NO303632 B1 NO 303632B1
Authority
NO
Norway
Prior art keywords
biphenylsulfonylurethane
biphenylsulfonylurea
derivative
side chains
preparations containing
Prior art date
Application number
NO930817A
Other languages
English (en)
Norwegian (no)
Other versions
NO930817D0 (no
NO930817L (no
Inventor
Holger Heitsch
Rainer Henning
Adalbert Wagner
Hermann Gerhards
Reinhard Becker
Bernward Schoelkens
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO930817D0 publication Critical patent/NO930817D0/no
Publication of NO930817L publication Critical patent/NO930817L/no
Publication of NO303632B1 publication Critical patent/NO303632B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO930817A 1992-03-07 1993-03-05 Imidazolderivater med bifenylsulfonylurea- eller bifenylsulfonyluretan-sidekjeder samt preparat inneholdende et slikt derivat NO303632B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4207241 1992-03-07

Publications (3)

Publication Number Publication Date
NO930817D0 NO930817D0 (no) 1993-03-05
NO930817L NO930817L (no) 1993-09-08
NO303632B1 true NO303632B1 (no) 1998-08-10

Family

ID=6453463

Family Applications (1)

Application Number Title Priority Date Filing Date
NO930817A NO303632B1 (no) 1992-03-07 1993-03-05 Imidazolderivater med bifenylsulfonylurea- eller bifenylsulfonyluretan-sidekjeder samt preparat inneholdende et slikt derivat

Country Status (25)

Country Link
US (1) US5604251A (fr)
EP (1) EP0560177B1 (fr)
JP (1) JP3542813B2 (fr)
KR (1) KR930019637A (fr)
CN (1) CN1036341C (fr)
AT (1) ATE230732T1 (fr)
AU (1) AU663565B2 (fr)
BR (1) BR9300761A (fr)
CA (1) CA2091135A1 (fr)
CZ (1) CZ281983B6 (fr)
DE (1) DE59310323D1 (fr)
DK (1) DK0560177T3 (fr)
ES (1) ES2187501T3 (fr)
FI (1) FI930970A (fr)
HU (1) HUT64041A (fr)
IL (1) IL104971A0 (fr)
MA (1) MA22814A1 (fr)
NO (1) NO303632B1 (fr)
NZ (1) NZ247059A (fr)
PH (1) PH31466A (fr)
PL (1) PL173023B1 (fr)
RU (1) RU2116300C1 (fr)
SK (1) SK381192A3 (fr)
TW (1) TW215434B (fr)
ZA (1) ZA931585B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
JP3501484B2 (ja) * 1992-12-17 2004-03-02 三共株式会社 ビフェニル誘導体
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
SG87052A1 (en) 1996-02-20 2002-03-19 Bristol Myers Squibb Co Pinacol ester intermediates useful for the preparation of biphenyl isoxazole sulfonamides
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
EP0944312B9 (fr) * 1996-12-13 2006-07-05 ZymoGenetics, Inc. Compositions visant a stimuler la croissance osseuse et methodes afferentes
EP0855392A3 (fr) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Hétérocycles à cinq chaínons contenant des substituants biphénylylsulphoniques, leur procédé de préparation, leur utilisation comme médicament ou agent diagnostique ainsi que médicament les contenant
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
WO1998033781A1 (fr) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Procede pour prevenir ou traiter l'hypertension due a une baisse de secretion de la renine, par l'administration d'un antagoniste de l'endotheline
US6201165B1 (en) 1997-10-16 2001-03-13 Board Of Regents, University Of Texas System Transgenic animal models for cardiac hypertrophy and methods of use thereof
DE19802969A1 (de) 1998-01-27 1999-07-29 Hoechst Marion Roussel De Gmbh Verfahren zur Herstellung von S-Alkyl(Aryl)-substituierten Imidazol-Derivaten
DE19820064A1 (de) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832428A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
JP2002540088A (ja) 1999-03-19 2002-11-26 ブリストル−マイヤーズ スクイブ カンパニー ビフェニルイソキサゾール・スルホンアミド化合物の製造法
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
US20040082613A1 (en) * 2002-06-28 2004-04-29 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
CA2526423A1 (fr) * 2003-05-21 2004-12-29 Board Of Regents, The University Of Texas System Inhibition de la proteine kinase c-mu (pkd) dans le traitement de l'hypertrophie cardiaque et de l'insuffisance cardiaque
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CN1984660B (zh) * 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
WO2005042487A1 (fr) * 2003-11-03 2005-05-12 Myogen, Inc. Composes1,4-dihydropyridine, compositions pharmaceutiques et methodes de traitement des maladies cardiovasculaires
US7485653B2 (en) * 2003-11-03 2009-02-03 Gilead Sciences, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
WO2005058280A2 (fr) * 2003-12-12 2005-06-30 Myogen, Inc. Preparations a base d'enoximone et leur utilisation pour traiter l'hypertrophie cardiaque et l'insuffisance cardiaque
US20060030611A1 (en) * 2004-03-22 2006-02-09 Myogen, Inc. Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
JP2007530563A (ja) * 2004-03-22 2007-11-01 ミオゲン インコーポレイティッド （ｓ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
WO2006007213A1 (fr) * 2004-06-23 2006-01-19 Myogen, Inc. Formulations d'enoximone et utilisation dans le traitement de maladies a mediation par pde-iii
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1833482A4 (fr) 2005-01-03 2011-02-16 Myriad Genetics Inc Composés bicycliques azotés et utilisation thérapeutique associée
US20090220507A1 (en) * 2005-07-22 2009-09-03 Sucharov Carmen C Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure
US20090306373A1 (en) * 2005-12-20 2009-12-10 Gamber Gabriel G 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions
PT2056882E (pt) 2006-08-01 2012-11-19 Univ Texas Identificação de um micro-rna que ativa a expressão da cadeia pesada de beta-miosina
CN101883576B (zh) 2007-07-31 2015-08-19 得克萨斯系统大学董事会 调控纤维化的微小rna家族及其用途
US8202848B2 (en) 2008-03-17 2012-06-19 Board Of Regents, The University Of Texas System Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1334092C (fr) * 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (fr) * 1988-01-07 1996-04-09 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5135197A (en) * 1990-08-30 1992-08-04 Qualtec Data Products, Inc. Equipment security method and apparatus
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
US5087634A (en) * 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
CA2058198A1 (fr) * 1991-01-04 1992-07-05 Adalbert Wagner Procede de preparation et utilisation de derives d'azole
US5236928A (en) * 1991-03-19 1993-08-17 Merck & Co., Inc. Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
WO1993004045A1 (fr) * 1991-08-19 1993-03-04 E.I. Du Pont De Nemours And Company Derives d'imidazolinone d'inhibition de l'action de l'angiotensine ii sur ses recepteurs
DE4221009A1 (de) * 1992-06-26 1994-01-05 Bayer Ag Imidazolyl-substituierte Cyclohexanderivate
JP3501484B2 (ja) * 1992-12-17 2004-03-02 三共株式会社 ビフェニル誘導体

Also Published As

Publication number Publication date
NO930817D0 (no) 1993-03-05
HU9300618D0 (en) 1993-05-28
CN1076192A (zh) 1993-09-15
MA22814A1 (fr) 1993-10-01
DE59310323D1 (de) 2003-02-13
AU663565B2 (en) 1995-10-12
TW215434B (fr) 1993-11-01
US5604251A (en) 1997-02-18
FI930970A0 (fi) 1993-03-04
CA2091135A1 (fr) 1993-09-08
ES2187501T3 (es) 2003-06-16
CZ281983B6 (cs) 1997-04-16
CN1036341C (zh) 1997-11-05
DK0560177T3 (da) 2003-04-14
SK279109B6 (sk) 1998-06-03
NZ247059A (en) 1995-03-28
RU2116300C1 (ru) 1998-07-27
PL297955A1 (en) 1993-09-20
EP0560177B1 (fr) 2003-01-08
AU3401193A (en) 1993-09-09
SK381192A3 (en) 1998-06-03
FI930970A (fi) 1993-09-08
CZ381192A3 (en) 1993-12-15
JP3542813B2 (ja) 2004-07-14
HUT64041A (en) 1993-11-29
PL173023B1 (pl) 1998-01-30
KR930019637A (ko) 1993-10-18
PH31466A (en) 1998-11-03
BR9300761A (pt) 1993-09-14
IL104971A0 (en) 1993-07-08
ZA931585B (en) 1993-09-27
NO930817L (no) 1993-09-08
EP0560177A1 (fr) 1993-09-15
ATE230732T1 (de) 2003-01-15
JPH069572A (ja) 1994-01-18

Similar Documents

Publication Publication Date Title
NO303632B1 (no) Imidazolderivater med bifenylsulfonylurea- eller bifenylsulfonyluretan-sidekjeder samt preparat inneholdende et slikt derivat
ATE247644T1 (de) Imidazo-annellierte iso- und heterocyclen, antagonisten als angiotensin ii
ATE183182T1 (de) S-triazinderivate als lichtschutzmittel
NO308300B1 (no) Heterosykliske forbindelser med tachykininreseptorantagonistaktivitet, og preparat inneholdende disse
ATE243697T1 (de) Substitutierte heterozyclische derivate als crf antagonisten
RU93004577A (ru) Производные имидазола с боковой цепью бифенилсульфонилмочевины
DE69628276D1 (de) Zubereitung von xanthinderivaten als feste dispersion
ATE305781T1 (de) Non-peptidische vasopressin via antagonisten
ES2161713T3 (es) Derivado de metotrexato.
DE69528983D1 (de) Indolalkaloide als antientzündliche wirkstoffe
AU2876292A (en) 2-((imidazol-2-yl)methyl)-isoindole derivatives as alpha-2-adrenoceptor antagonists
FI963568A0 (fi) Peptidijohdannaisia
DE59505429D1 (de) Alkyl-5-methylsulfonyl-benzoyl-guanidin-Derivate
MD287B1 (ro) Preparat pentru indicarea catalazei microbiene